Expanded Access to ANG1005 for Individual Patients
| Status: | No longer available |
|---|---|
| Conditions: | Brain Cancer, Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/21/2016 |
Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma.
This is an expanded access study with ANG1005 treatment for two individual patients from
Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III
Anaplastic Oligodendroglioma.
Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III
Anaplastic Oligodendroglioma.
Inclusion Criteria:
1. Neurologically stable
2. Karnofsky performance status (KPS) ≥ 80
3. Adequate laboratory results
Exclusion Criteria:
1. Radiotherapy within 3 months.
2. Evidence of significant intracranial hemorrhage
3. NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade ≥ 2 neuropathy
4. Inadequate bone marrow reserve
5. Any evidence of severe or uncontrolled disease
We found this trial at
1
site
San Antonio, Texas 78229
Principal Investigator: Andrew Brenner, MD
Phone: 210-450-5976
Click here to add this to my saved trials
